TherapeuticsMD, Inc. TXMD
2.05
(0.08)
(3.76%)
as of 25 Sep
- Market cap
- $24.7M
- P/E
- 0.0×
Follow TXMD
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
1.11% | (2.10%) | 0.67% | (0.80%) | |
| 0.77% | (1.49%) | 0.47% | (0.57%) | ||
ROIC |
(11.94%) | (14.15%) | (12.91%) | (13.77%) | |
Return on Tangible Assets |
3.16% | (5.89%) | 1.73% | (1.95%) | |
Average Days of Receivables |
478.44 | 425.75 | 349.54 | 378.84 | |
Free Cash Flow per Share |
0.18 | 0.21 | 0.23 | 0.27 | |
Free Cash Flow |
2.10 | 2.45 | 2.70 | 3.10 | |
Piotroski F-Score |
6.00 | 5.00 | 6.00 | 5.00 | |
| Other line items | |||||
Cash ROIC |
6.06% | 7.14% | 7.63% | 8.53% | |
Accounts Receivable Turnover |
0.80 | 0.85 | 1.08 | 0.92 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
220.57% | 226.74% | 200.24% | 206.12% | |
Share Based Compensation of Revenue |
1.72% | 2.48% | 1.61% | 1.74% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
6.94 | (4.31) | 15.08 | (14.27) | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.24 | 0.26 | 0.29 | 0.28 | |
Operating CF per Share |
0.18 | 0.21 | 0.23 | 0.27 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
10.80% | (18.83%) | 5.34% | (6.64%) |
Columns are period end dates